Minoxidil
As of the edition of 20 October 2026, Minoxidil is a small molecule: marketed, first approved in 1980 (CA); acts on ABCC9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1983
- Kind
- Small molecule
- Brand name
- Loniten
- First approved
- 31 December 1980 (CA)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- Kenvue Brands; 2 holders in all
- Registered trials
- 45, 1 stopped early
- Disease areas
- Skin and connective tissue; Cancer; Heart and blood vessels; Hormones; Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Minoxidil.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ABCC9 | ATP-binding cassette sub-family C member 9 | O60706 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 3 | 3 | 0 |
| Phase 1 | 8 | 2 | 4 | 0 |
| Phase 2 | 10 | 4 | 2 | 1 |
| Phase 3 | 15 | 10 | 4 | 0 |
| Phase 4 | 4 | 3 | 0 | 0 |
| All trials | 45 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant | 1980 to now |
| Kenvue Brands | Acquired holder | 2025 to now |